Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL4303836 Target Snapshot

SARS-CoV · ORGANISM · Severe acute respiratory syndrome-related coronavirus

Back to Search Search this target Browse approvals Evidence Card
246Compounds
127Assays
22Approved Drugs
292.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Confirm a stable target identifier before relying on this context across project surfaces.

Review focus
Open DB context pending

Confirm a stable target identifier before relying on this context across project surfaces.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats SARS-CoV as ChEMBL target CHEMBL4303836. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
SARS-CoV
ORGANISM · Severe acute respiratory syndrome-related coronavirus
As of 2026-09-13
ChEMBL target ID
CHEMBL4303836
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether SARS-CoV still has a stable protein naming contract across sources.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameSARS-CoV
Target TypeORGANISM
OrganismSevere acute respiratory syndrome-related coronavirus
ChEMBL ↗ NCBI Taxonomy ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelSARS-CoV
UniProt AccessionN/A

SARS-CoV

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as SARS-CoV.

Review nameSARS-CoV
OrganismSevere acute respiratory syndrome-related coronavirus
Clinical Profile

Clinical Phase Distribution

22
Approved
6
Phase III
7
Phase II
1
Phase I
Assay Mix

Activity Type Distribution

IC5084.0
EC50208.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL5198546 10.4 IC50 0.04 Preclinical
CHEMBL5190923 10.4 IC50 0.04 Preclinical
CHEMBL5185113 10.4 IC50 0.04 Preclinical
CHEMBL5181012 10.4 IC50 0.04 Preclinical
CHEMBL4755358 10.4 IC50 0.04 Preclinical
CHEMBL4743491 10.4 IC50 0.04 Preclinical
CHEMBL91704 9.49 IC50 0.32 Clinical
CHEMBL400092 7.8 EC50 15.7 Preclinical
CHEMBL400092 7.8 IC50 15.7 Preclinical
CHEMBL490820 7.52 IC50 30.0 Preclinical
Distribution

pChEMBL Value Distribution

57
5.0
52
5.5
16
6.0
12
6.5
14
7.0
4
7.5
0
8.0
0
8.5
2
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

NIRMATRELVIR
CHEMBL4802135
Approved 2023
Properties Compare Identifier
REMDESIVIR
CHEMBL4065616
Approved 2020
Properties Compare Identifier
NELFINAVIR
CHEMBL584
Approved 1997
Properties Compare Identifier
Assay Landscape

Assay Landscape

127
Total Assays
168
Tested Compounds
2
Assay Types
Functional — 126 assays, 168 compounds
BAO Format Assays Compounds Avg pChEMBL
organism-based format 126 168 5.7
ADME — 1 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
organism-based format 1 0 —

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine